Log In
BCIQ
Print this Print this
 

NPT200-11, UCB1332

  Manage Alerts
Collapse Summary General Information
Company Neuropore Therapies Inc.
DescriptionAlpha synuclein (SNCA) oligomerization inhibitor
Molecular Target Alpha synuclein (SNCA)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerUCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$480.0M

$20.0M

$460.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/16/2015

$480.0M

$20.0M

$460.0M

Get a free BioCentury trial today